The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.

Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.

Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

The company's comparison of its ADCs to Enhertu seems farfetched.

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.